CN109415403A - 作为化学中间体的类固醇6.7.β-环氧化物 - Google Patents

作为化学中间体的类固醇6.7.β-环氧化物 Download PDF

Info

Publication number
CN109415403A
CN109415403A CN201780030408.5A CN201780030408A CN109415403A CN 109415403 A CN109415403 A CN 109415403A CN 201780030408 A CN201780030408 A CN 201780030408A CN 109415403 A CN109415403 A CN 109415403A
Authority
CN
China
Prior art keywords
compound
alkyl
general formula
group
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201780030408.5A
Other languages
English (en)
Chinese (zh)
Inventor
A·C·韦茅斯-威尔逊
Z·科姆斯塔
L·沃利斯
I·戴维斯
王璟婧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nzp Uk Ltd
Original Assignee
Nzp Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nzp Uk Ltd filed Critical Nzp Uk Ltd
Publication of CN109415403A publication Critical patent/CN109415403A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780030408.5A 2016-05-18 2017-05-18 作为化学中间体的类固醇6.7.β-环氧化物 Withdrawn CN109415403A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1608779.3 2016-05-18
GBGB1608779.3A GB201608779D0 (en) 2016-05-18 2016-05-18 Methods and compounds
PCT/GB2017/051393 WO2017199039A1 (en) 2016-05-18 2017-05-18 Steroid 6.7.beta.-epoxides as chemical intermediates

Publications (1)

Publication Number Publication Date
CN109415403A true CN109415403A (zh) 2019-03-01

Family

ID=56320631

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780030408.5A Withdrawn CN109415403A (zh) 2016-05-18 2017-05-18 作为化学中间体的类固醇6.7.β-环氧化物

Country Status (13)

Country Link
US (1) US20190153023A1 (https=)
EP (1) EP3458468B1 (https=)
JP (1) JP7034092B2 (https=)
KR (1) KR102509432B1 (https=)
CN (1) CN109415403A (https=)
AU (1) AU2017265925A1 (https=)
BR (1) BR112018073490A2 (https=)
CA (1) CA3024285A1 (https=)
EA (1) EA037742B1 (https=)
ES (1) ES2857869T3 (https=)
GB (1) GB201608779D0 (https=)
MX (1) MX377644B (https=)
WO (1) WO2017199039A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113912661A (zh) * 2021-11-11 2022-01-11 湖南科瑞生物制药股份有限公司 一种7-羟基甾体化合物的合成方法
CN114702542A (zh) * 2022-05-11 2022-07-05 上海其正医药科技有限责任公司 一种25-羟基-7-去氢胆固醇的制备方法
CN115974950A (zh) * 2022-12-23 2023-04-18 上海彩迩文生化科技有限公司 一种3-烷基化的甾体中间体及其制备和应用
WO2026026994A1 (zh) * 2024-07-28 2026-02-05 湖北共同甾体药物研究院有限公司 熊去氧胆酸中间体的制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608776D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
EP3431486A1 (en) * 2017-07-18 2019-01-23 Bionice, S.L.U. Process and intermediates for the synthesis of obeticholic acid and derivatives thereof
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN111072744B (zh) * 2019-12-03 2021-09-14 江苏佳尔科药业集团股份有限公司 一种以ba为原料合成熊去氧胆酸的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1985621A1 (en) * 2006-01-12 2008-10-29 Mitsubishi Chemical Corporation Process for production of steroids
CN101374854A (zh) * 2006-01-12 2009-02-25 三菱化学株式会社 甾类化合物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
CN107207559B (zh) * 2014-11-19 2019-10-25 Nzp英国有限公司 作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇
KR102527821B1 (ko) * 2014-11-19 2023-05-02 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
KR102546748B1 (ko) * 2014-11-19 2023-06-22 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드
EA033445B1 (ru) * 2014-11-19 2019-10-31 Nzp Uk Ltd 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1985621A1 (en) * 2006-01-12 2008-10-29 Mitsubishi Chemical Corporation Process for production of steroids
CN101374854A (zh) * 2006-01-12 2009-02-25 三菱化学株式会社 甾类化合物的制备方法

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113912661A (zh) * 2021-11-11 2022-01-11 湖南科瑞生物制药股份有限公司 一种7-羟基甾体化合物的合成方法
CN114702542A (zh) * 2022-05-11 2022-07-05 上海其正医药科技有限责任公司 一种25-羟基-7-去氢胆固醇的制备方法
CN114702542B (zh) * 2022-05-11 2023-11-24 上海其正医药科技有限责任公司 一种25-羟基-7-去氢胆固醇的制备方法
CN115974950A (zh) * 2022-12-23 2023-04-18 上海彩迩文生化科技有限公司 一种3-烷基化的甾体中间体及其制备和应用
WO2026026994A1 (zh) * 2024-07-28 2026-02-05 湖北共同甾体药物研究院有限公司 熊去氧胆酸中间体的制备方法

Also Published As

Publication number Publication date
EA037742B1 (ru) 2021-05-17
US20190153023A1 (en) 2019-05-23
AU2017265925A1 (en) 2018-11-15
JP2019516717A (ja) 2019-06-20
ES2857869T3 (es) 2021-09-29
WO2017199039A1 (en) 2017-11-23
MX377644B (es) 2025-03-04
KR102509432B1 (ko) 2023-03-13
JP7034092B2 (ja) 2022-03-11
EP3458468B1 (en) 2020-12-09
CA3024285A1 (en) 2017-11-23
EA201892515A1 (ru) 2019-05-31
KR20190006187A (ko) 2019-01-17
GB201608779D0 (en) 2016-06-29
BR112018073490A2 (pt) 2019-03-26
MX2018014128A (es) 2019-04-29
EP3458468A1 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
CN109415403A (zh) 作为化学中间体的类固醇6.7.β-环氧化物
CN109415407B (zh) 用于合成胆汁酸衍生物、特别是奥贝胆酸的中间体
EP3221331B1 (en) 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
KR102546748B1 (ko) 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드
KR102526632B1 (ko) 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 5β-6-알킬-7-하이드록시-3-온 스테로이드
CN109415404B (zh) 用于类固醇4,6-二烯的6,7-α-环氧化的方法和中间体
HK1244285A1 (en) 5.beta -6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
HK40055816A (en) Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid
HK40055816B (en) Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid
HK40006371A (en) Steroid 6.7.beta.-epoxides as chemical intermediates
HK40006371B (en) Steroid 6.7.beta.-epoxides as chemical intermediates
CA3024281C (en) Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid
HK40006370B (en) Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid
JPH037680B2 (https=)
HK40006372B (en) Process for the 6,7-alpha-epoxidation of steroid 4,6-dienes
HK40006372A (en) Process for the 6,7-alpha-epoxidation of steroid 4,6-dienes
HK1246801B (en) 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
BR112018073488B1 (pt) Intermediários para a síntese de derivados de ácido biliar, em particular de ácido obeticólico e seu processo de preparação

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20190301

WW01 Invention patent application withdrawn after publication